Disease · MONDO_0020546

acute graft versus host disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute graft versus host disease. Diseases, record MONDO_0020546. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020546

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute graft versus host disease; Open Targets
Open Targets ID: MONDO_0020546; Open Targets
Other names: GVHD, acute, acute graft vs. host disease, fulminant graft versus host disease, graft versus host disease, acute; Open Targets
NCI Thesaurus: C4980; NCI Thesaurus
Orphanet: ORPHA:99920; Orphanet
Highest stage of its drugs: Phase 3, for 19 of its 59 drugs, from ClinicalTrials.gov; Open Targets

Drugs59

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	18	18	10	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	13	13	3	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	9	9	0	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	8	8	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	8	8	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	8	8	0	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 3	ClinicalTrials.gov	8	8	0	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
BASILIXIMAB	CHEMBL1201439	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 59

See all 59 drugs

Targets78

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	13	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
IL2RA	Interleukin-2 receptor	3	Interleukin-2 receptor agonist; Interleukin-2 receptor binding agent; Interleukin-2 receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	3	Interleukin-2 receptor agonist; Interleukin-2 receptor binding agent; Interleukin-2 receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	3	Interleukin-2 receptor agonist; Interleukin-2 receptor binding agent; Interleukin-2 receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3561	Drugs and targets
DPP4	Dipeptidyl peptidase 4	2	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
ITGA4	Integrin alpha-4/beta-1	2	Integrin alpha-4/beta-1 inhibitor; Integrin alpha-4/beta-7 inhibitor	Phase 2	https://conductscience.org/library/genes/3676	Drugs and targets
ITGB7	Integrin alpha-4/beta-7	2	Integrin alpha-4/beta-7 inhibitor	Phase 2	https://conductscience.org/library/genes/3695	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	2	Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	2	Luteinizing hormone/Choriogonadotropin receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3973	Drugs and targets

1 to 10 of 78

See all 78 targets

Trials63

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02913261	Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation	Phase 3	310	2023-02-08	Corticosteroid Refractory Acute Graft vs Host Disease	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00224874	Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)	Phase 2	180	2010-04-09	Graft vs Host Disease, Immune System Disorders	DENILEUKIN DIFTITOX, ETANERCEPT, MYCOPHENOLATE MOFETIL, PENTOSTATIN	Its record names the disease	ClinicalTrials.gov
NCT00189488	Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation	Phase 2	155	2014-09-15	Graft Versus Host Disease, Hematologic Malignancies	PALIFERMIN	Its record names the disease	ClinicalTrials.gov
NCT02806947	A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)	Phase 2	127	2019-12-17	Acute GVHD	PREDNISONE, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02133924	Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease	Phase 2	76	2022-10-21	Acute Graft Versus Host Disease	NATALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02953678	A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)	Phase 2	71	2019-08-20	Graft-versus-host Disease (GVHD)	METHYLPREDNISOLONE, PREDNISONE, RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT02336230	A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)	Phase 3	55	2022-03-17	Grade B aGVHD, Grade C aGVHD, Grade D aGVHD	REMESTEMCEL-L	Its record names the disease	ClinicalTrials.gov
NCT03491215	Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease	Phase 1/2	45	2024-11-08	Acute Graft Versus Host Disease	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT00496340	Phase II Trial of Pentostatin and Targeted Busulfan	Phase 2	42	2014-06-05	Hematologic Malignancies	BUSULFAN, PENTOSTATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01700036	A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease	Phase 2	40	2018-01-05	Graft vs Host Disease	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 63

See all 63 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Palifermin vs Placebo: serious adverse events	50 of 78	40 of 73	151	NCT00189488	Trial comparisons
Sirolimus vs Prednisone: deaths from any cause	12 of 58	17 of 64	122	NCT02806947	Trial comparisons
Sirolimus vs Prednisone: serious adverse events	8 of 58	3 of 64	122	NCT02806947	Trial comparisons
BEGEDINA® (Begelomab) vs Conventional Second-line Treatment: deaths from any cause	13 of 18	8 of 18	36	NCT02411084	Trial comparisons
BEGEDINA® (Begelomab) vs Conventional Second-line Treatment: serious adverse events	16 of 18	13 of 18	36	NCT02411084	Trial comparisons
Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs)	8 of 8	9 of 9	17	NCT02993783	Trial comparisons
Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Week 32	6 of 8	9 of 9	17	NCT02993783	Trial comparisons
Vedolizumab 300 mg vs Vedolizumab 600 mg: Number of Participants Who Experienced Serious Adverse Events (SAEs) Through Day 28	3 of 8	4 of 9	17	NCT02993783	Trial comparisons
Vedolizumab 300 mg vs Vedolizumab 600 mg: deaths from any cause	4 of 8	9 of 9	17	NCT02993783	Trial comparisons
Vedolizumab 300 mg vs Vedolizumab 600 mg: serious adverse events	6 of 8	9 of 9	17	NCT02993783	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials35

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39438467	RESULT	2	PubMed
37749187	RESULT	1	PubMed
35668528	RESULT	2	PubMed
33536914	RESULT	1	PubMed
20541024	RESULT	1	PubMed
19925875	RESULT	1	PubMed
19443659	RESULT	1	PubMed
42180389	DERIVED	1	PubMed
41092247	DERIVED	1	PubMed
40794300	DERIVED	1	PubMed

1 to 10 of 35

See all 35 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020546

GET https://conductscience.org/api/diseases/v1/MONDO_0020546/drugs?page=2

API reference For AI assistants